Fenobate 67mg Capsule contains Fenofibrate, a lipid-modifying agent primarily used to manage hyperlipidemia and hypertriglyceridemia. Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), which leads to increased oxidation of fatty acids and a reduction in triglyceride-rich lipoproteins. This action helps lower elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol while increasing high-density lipoprotein (HDL) cholesterol, thereby reducing the risk of cardiovascular disease associated with lipid abnormalities. Fenobate is indicated for patients with primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia who have not responded adequately to diet and lifestyle modifications alone. The 67mg capsule dosage is typically prescribed based on individual patient needs and lipid profile goals, and it should be taken with food to enhance absorption. Common side effects may include gastrointestinal discomfort, headache, and elevated liver enzymes, so regular monitoring of liver function and lipid levels is recommended during therapy. Fenobate should be used cautiously in patients with renal impairment and is contraindicated in those with severe liver disease or gallbladder disease. Overall, Fenobate 67mg Capsule is an effective option for improving lipid profiles and reducing cardiovascular risk when used as part of a comprehensive treatment plan.